maziar mike doustdar novo nordisk - Search News

News

Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar

Reuters on MSN · 4d

Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO, shares plunge

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug Wegovy is falling behind in a race it started.

The Wall Street Journal on MSN · 2d

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

Danish leader will face a challenging landscape among competitors

PharmExec · 4d

Novo Nordisk Names Maziar Mike Doustdar as President and Chief Executive Officer

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief executive officer (CEO). Jørgensen will step down from his current role serving as president and CEO on the same day Doustdar is expected to take over.

1don MSN

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Novo Nordisk Announces New CEO Amidst Weight-Loss Drug Competition

Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...

1d

Novo Nordisk Shares Dip Further as Wegovy Gains Nearly Erased

(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results